1. Introduction {#sec1-geriatrics-05-00017}
===============

Frailty, defined as a geriatric syndrome characterised by increased vulnerability to even minor stressors and decreased physiological reserve \[[@B1-geriatrics-05-00017],[@B2-geriatrics-05-00017]\], is common among older people. Globally, it has been estimated that about 4.3% of older adults aged 60 years and older will develop frailty per year \[[@B3-geriatrics-05-00017]\]. However, the prevalence of frailty varies widely among older people: 4.0--59.1% in community-dwelling older adults \[[@B4-geriatrics-05-00017]\], 10.4--37.0% in general surgery patients \[[@B5-geriatrics-05-00017]\], 6.0--86.0% in cancer patients \[[@B6-geriatrics-05-00017]\], and 19.0--75.6% in nursing home residents \[[@B7-geriatrics-05-00017]\].

Numerous studies have shown frailty to be associated with many negative health outcomes including increased risk of hospitalizations \[[@B8-geriatrics-05-00017]\], disability \[[@B9-geriatrics-05-00017]\], falls \[[@B10-geriatrics-05-00017]\], fractures \[[@B11-geriatrics-05-00017]\], delirium \[[@B12-geriatrics-05-00017]\], and institutionalization \[[@B13-geriatrics-05-00017]\]. Owing to these adverse effects, frailty is associated with higher healthcare use and cost burden \[[@B14-geriatrics-05-00017],[@B15-geriatrics-05-00017],[@B16-geriatrics-05-00017]\].

Moreover, frailty has been associated with increased risk of mortality and premature death \[[@B1-geriatrics-05-00017],[@B17-geriatrics-05-00017],[@B18-geriatrics-05-00017]\], and this effect has been suggested to be stable across different generational cohorts \[[@B19-geriatrics-05-00017]\]. In particular, Shamliyan and colleagues have suggested that 3--5% of deaths among community-dwelling adults could be averted if there are concerted efforts to prevent frailty \[[@B20-geriatrics-05-00017]\]. The exact mechanisms underpinning increased mortality among people who are frail remains unclear, although, there are suggestions that reduced physical and cognitive functions associated with frailty leads to poor prognosis \[[@B21-geriatrics-05-00017],[@B22-geriatrics-05-00017]\]. Others have also indicated that it is the underlying clinical conditions associated with frailty that are ultimately the cause of death \[[@B23-geriatrics-05-00017],[@B24-geriatrics-05-00017]\]. For example, an underlying physical or even psychological condition can give rise to weight loss, which contributes to the development of frailty \[[@B25-geriatrics-05-00017]\]. Whether or not the effects of frailty on mortality risk are ubiquitous or more profound in selected subgroups is also unclear.

Thus, this umbrella review summarizes evidence generated from systematic reviews and meta-analyses that examined the association between frailty and all-cause mortality across different population groups and settings.

2. Methods {#sec2-geriatrics-05-00017}
==========

This review was performed according to the recommendations outlined in the Meta-analysis of Observational Studies in Epidemiology \[[@B26-geriatrics-05-00017]\], the Preferred Reporting Items for Systematic Reviews and Meta-Analyses statements \[[@B27-geriatrics-05-00017]\] ([Supplementary Table S1](#app1-geriatrics-05-00017){ref-type="app"}), and the Cochrane Collaboration Handbook \[[@B28-geriatrics-05-00017]\].

2.1. Search Strategy and Study Selection {#sec2dot1-geriatrics-05-00017}
----------------------------------------

A systematic literature search of Medline, Embase, CINAHL, Web of Science, PsycINFO, and AMED (allied and complementary medicine) databases for systematic reviews and meta-analyses examining the association between frailty and the risk of all-cause mortality. The search was first performed in August 2019 and was last updated in February 2020. The main keywords used included "frailty OR frailty syndrome OR frail elderly OR geriatric syndrome OR geriatric disorder" AND "systematic review OR meta-analysis OR review". The full search strategy is presented in [Supplementary Table S2](#app1-geriatrics-05-00017){ref-type="app"}. In addition, the reference lists of included systematic reviews and meta-analyses were manually screened. The literature search was independently performed by two reviewers (RO and KLC), and disagreements were resolved by consensus involving a third author (BWS).

2.2. Selection Criteria {#sec2dot2-geriatrics-05-00017}
-----------------------

The inclusion criteria were as follows: (1) participants: any population; (2) study design: meta-analyses that reported pooled risk estimates (hazard ratios \[HRs\] or risk ratios \[RRs\]; (3) exposure: frailty or pre-frailty as defined by any criteria; and (4) outcome: risk of all-cause mortality. We restricted the review to only studies reporting HRs and RRs as these are measures are largely comparable, and in other reviews have been pooled together \[[@B28-geriatrics-05-00017]\]. The exclusion criteria were as follows: (1) studies published in languages other than English; (2) meta-analyses that did not follow the methodology of a systematic review; (3) meta-analyses that pooled frailty scores without categorisation; and (4) systematic reviews without meta-analysis.

2.3. Data Extraction {#sec2dot3-geriatrics-05-00017}
--------------------

Two researchers (KLC and BWS) independently extracted the following data from the original studies using a standardized data collection form: (1) author identification and year of publication; (2) databases searched for systematic review; (3) search date; (*4*) number of studies included; (5) age of the participants; (6) length of follow-up; (7) number of frail and non-frail populations; (8) frailty assessment tool used; (9) reported risk estimates; (8) heterogeneity reported; and (9) AMSTAR2 risk of bias rating \[[@B29-geriatrics-05-00017]\]. We also extracted age- or sex-specific risk estimates if reported. Where studies reported effect of frailty at different follow-up periods, we prioritized the data on long-term mortality effects. Disagreements in data collection were resolved by discussion involving a third author (RO).

2.4. Quality Assessment {#sec2dot4-geriatrics-05-00017}
-----------------------

Two investigators (BS and KLC) independently assessed the methodological quality of each study after concealment of information about the authors, affiliations, date and source. A standardized checklist, the AMSTAR2 appraisal tool, for reporting systematic reviews and meta-analyses was used \[[@B29-geriatrics-05-00017]\]. This checklist includes 16 criteria, each referring to a relevant methodological aspect of the study. For each review, we applied a rating of high, moderate, low, or critically low for the overall confidence in the results. The ratings were performed by two reviewers (BS and KLC) and any disagreements were resolved via consensus involving third reviewer (RO).

2.5. Data Synthesis {#sec2dot5-geriatrics-05-00017}
-------------------

To depict the relationship between frailty and all-cause mortality, the risk estimates (HR/RR) and corresponding 95% confidence intervals (CIs) for each meta-analysis were displayed in a forest plot \[[@B30-geriatrics-05-00017],[@B31-geriatrics-05-00017],[@B32-geriatrics-05-00017]\]. Using the point HR/RR from each study, we also calculated the median risk estimate along with corresponding interquartile range (IQR) to describe the distribution of the reported effect of frailty on all-cause mortality. The level of heterogeneity across individual meta-analysis was assessed via the *I*^2^ statistic, and depending on its values heterogeneity was considered as the following: might not be important (0--40%), may represent moderate heterogeneity (30--60%), substantial heterogeneity (50--90%), or considerable heterogeneity (75--100%) \[[@B28-geriatrics-05-00017]\]. Forest plots were produced using StataSE software version 16 (StataCorp, TX, USA), which displayed data from original meta-analyses without including any additional analyses.

3. Results {#sec3-geriatrics-05-00017}
==========

3.1. Characteristics of Included Studies {#sec3dot1-geriatrics-05-00017}
----------------------------------------

Our search identified 4930 citations. A total of 150 articles were selected for full text examination while others were removed following initial screening based on titles and abstract or duplicates. Of the 150 articles, 24 were eligible for analysis. One additional study was retrieved via reference screening. The studies' selection process is summarised in [Figure 1](#geriatrics-05-00017-f001){ref-type="fig"}.

The descriptive characteristics of the included studies are presented in [Table 1](#geriatrics-05-00017-t001){ref-type="table"}. The meta-analyses were published between 2015 and 2019 and included between three and 24 studies with sample sizes ranging from \<2000 to \>500,000 participants. All the systematic reviews and meta-analyses conducted their search in two or more databases. The meta-analyses focused on community-dwelling older adults (*n* = 3); patients who had undergone transcatheter aortic valve implantation or replacement (*n* = 3), percutaneous coronary intervention (PCI; *n* = 1), or left ventricular assist device implantation (*n* = 1); vascular surgery patients (*n* = 1); patients with chronic kidney disease or end-stage renal disease (*n* = 1); patients with heart failure (*n* = 4), diabetes (*n* = 1), acute coronary syndrome (ACS; *n* = 3), or multiple myeloma (*n* = 1); patients who had been admitted to an intensive care unit (ICU; *n* = 1), nursing home residents (*n* = 1); patients who had undergone a range of other surgical interventions (*n* = 3) or those hospitalized for a range of medical conditions (*n* = 1).

The heterogeneity (*I*^2^) across the individual meta-analyses was variable and ranged from 0% to 100%. Fifty-six percent (14/25) of studies reported substantial to a considerable level of heterogeneity. In the studies which reported frailty prevalence, the baseline prevalence of frailty ranged from 7.9% to 86.6%.

After evaluation of the risk of bias by the AMSTAR 2 tool, 56% (14/25), 32% (8/25), and 12% (3/25) were rated to be of moderate, low, and critically low quality, respectively. The critical domains that were most frequently lacking were justification for exclusion of individual studies (22 out of 25), lack of protocol being registered before review commencement (11 out of 25) and assessment of present and likely impact of publication bias (eight out of 25). The breakdown of the AMSTAR 2 assessment for each study is presented in [Supplementary Table S3](#app1-geriatrics-05-00017){ref-type="app"}.

3.2. Association Between Frailty and All-Cause Mortality {#sec3dot2-geriatrics-05-00017}
--------------------------------------------------------

A total of 24 meta-analyses reported the association between frailty and the risk of all-cause mortality. All 24 studies found that frailty was associated with increased risk of all-cause death. The reported HR/RRs of the effect of frailty on all-cause mortality ranged from 1.35 to 7.95. The lowest HR/RR was reported among diabetes patients and the highest among hospitalized patients. The median HR/RR estimate of frailty on all-cause mortality across the included studies was 1.98 (IQR 1.65--2.67). [Figure 2](#geriatrics-05-00017-f002){ref-type="fig"} displays a forest plot of the of the reported HR/RR of the association between frailty and all-cause mortality in the included studies. None of the studies reported age- or sex-specific pooled data.

3.3. Association between Pre-Frailty and All-Cause Mortality {#sec3dot3-geriatrics-05-00017}
------------------------------------------------------------

All seven meta-analyses that reported the association between pre-frailty and all-cause mortality found that pre-frailty was associated with increased risk of all-cause mortality. The reported HR/RRs of the effect of pre-frailty on all-cause mortality ranged from 1.09 among diabetes patients to 3.65 among hospitalized patients. The median HR/RR estimate of frailty on all-cause mortality across the included studies was 1.51 (IQR 1.38--1.73). [Figure 3](#geriatrics-05-00017-f003){ref-type="fig"} displays a forest plot of the association between pre-frailty and all-cause mortality in the included studies. None of the studies reported age- or sex-specific pooled data.

4. Discussion {#sec4-geriatrics-05-00017}
=============

Increasingly, frailty has been recognized as a marker of poor ageing \[[@B58-geriatrics-05-00017]\], and this syndrome is associated with many negative health outcomes \[[@B9-geriatrics-05-00017],[@B10-geriatrics-05-00017],[@B11-geriatrics-05-00017],[@B12-geriatrics-05-00017],[@B15-geriatrics-05-00017]\]. However, the absence of a lack of a universally accepted definition creates clinical and research conundrum \[[@B59-geriatrics-05-00017],[@B60-geriatrics-05-00017]\]. Moreover, while frailty is expressed over a broad spectrum of severity, defining the point at which frailty begins is challenging \[[@B1-geriatrics-05-00017]\]. An equally important issue also relates to identification of the tipping point at which the progression of frailty begins to exert negative effects on survival \[[@B20-geriatrics-05-00017]\].

With the above in mind, this overview of systematic reviews and meta-analyses provides a synthesis of the current available evidence of the association between frailty and the risk of all-cause mortality. We found consistent data across different populations and settings suggesting that both frailty and pre-frailty are associated with increased risk of all-cause mortality. Across the included studies, frailty was on average associated with a two-fold increased risk of death, although the risk of mortality associated with pre-frailty appeared to be much lower.

Although all the included studies suggested frailty and pre-frailty to be associated with increased risk of all-cause mortality, there was significant heterogeneity in the effect sizes. For example, while one study reported frailty to be associated with about two times increased risk of death in community-dwelling adults \[[@B42-geriatrics-05-00017]\], another study reported frailty to be associated with a nearly eight-fold increase in risk of mortality among patients hospitalized for a range of conditions \[[@B56-geriatrics-05-00017]\]. These data suggest that the mortality effect of frailty across different populations may be graded and could also be related to other underlying pathological risk factors/stressors that exacerbate the impact of frailty to varied extents in different populations \[[@B21-geriatrics-05-00017],[@B22-geriatrics-05-00017]\].

As frailty is associated with increased risk of mortality, screening for frailty may be useful for all older adults. However, frailty screening remains a highly debated issue especially in relation to screening eligibility, as well as where and when it should be performed \[[@B3-geriatrics-05-00017],[@B61-geriatrics-05-00017]\]. Regardless, within specialized geriatric ambulatory care settings and long-term care facilities, the use of comprehensive geriatric assessments that incorporate the deficit accumulation definition of frailty may be more feasible to screen for frailty \[[@B62-geriatrics-05-00017],[@B63-geriatrics-05-00017]\], whereas the frailty phenotype may be easier adopt within primary care settings to identify frail individuals \[[@B20-geriatrics-05-00017]\].

Healthcare providers need to recognize frailty both as an important baseline condition and an outcome among older adults. To this end, improved understanding of the risk factors of frailty is important. Several factors are associated with increased risk of frailty including individual chronic morbidities such as diabetes, cancers, or depression or their co-existence \[[@B3-geriatrics-05-00017],[@B64-geriatrics-05-00017],[@B65-geriatrics-05-00017]\]. Psychosocial (e.g., social isolation) and lifestyle factors also play important roles in the development of frailty \[[@B3-geriatrics-05-00017],[@B66-geriatrics-05-00017],[@B67-geriatrics-05-00017]\]. Regardless, studies also suggest that both frailty and pre-frailty can be reversed \[[@B68-geriatrics-05-00017],[@B69-geriatrics-05-00017]\]. Thus, to minimize the risk of frailty development, delay its progression or promote reversal, multidisciplinary interventions that aim to improve physical, cognitive, and social functioning are required \[[@B20-geriatrics-05-00017],[@B70-geriatrics-05-00017],[@B71-geriatrics-05-00017],[@B72-geriatrics-05-00017]\]. In the context of primary care settings, relative effectiveness and ease of implementation of programs at preventing or slowing frailty progression, ranked from highest to lowest, are strength training, protein supplementation, comprehensive geriatric assessments, home visits and behavioral change interventions \[[@B72-geriatrics-05-00017]\].

Although the present overview provides important insights, some limitations should be considered. First, the criteria for ascertaining death varied across the primary studies of the meta-analyses, and therefore misclassification may have affected the estimates of the association between frailty and the risk of mortality. Secondly, some primary studies may have been included in more than one meta-analysis and thus the influence of these studies would have been inflated. Thirdly, some meta-analyses involved primary studies that showed substantial heterogeneity, which may limit the validity of their, and hence our, conclusions. Furthermore, although the prevalence of frailty and its mortality effects could vary by age, sex or other characteristics \[[@B73-geriatrics-05-00017],[@B74-geriatrics-05-00017],[@B75-geriatrics-05-00017]\], we could not examine this in detail due to limited data. We could also not examine the presence of publication bias due to the design of our study and the methodology used. Moreover, some meta-analyses were based on small number of studies showed large effect sizes, which may be suggestive of publication bias in reviews. Lastly, further bias may have arisen from our limitation of component studies to English, although the extent of this bias, if present, would likely have been small.

5. Conclusions {#sec5-geriatrics-05-00017}
==============

Across different populations and settings, frailty defined using multiple criteria is associated with two-fold increased risk of all-cause mortality. Thus, public health interventions to prevent or slow the progression of frailty may prevent avoidable deaths.

The following are available online at <https://www.mdpi.com/2308-3417/5/1/17/s1>, Table S1: PRISMA Checklist; Table S2: Search strategy for Ovid Medline which was adapted to other databases; Table S3: AMSTAR2 grading for each study.
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geriatrics-05-00017-t001_Table 1

###### 

Descriptive characteristics of the included meta-analyses.

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Author                                               Databases Searched                                                                                                                 Search Period                     No. of Studies Pooled         Population/Setting                                                                       Age                      \% Women     Countries of Included Studies                                                                               Follow up\                   Total Sample (% Frail)   Exposures Assessed     Pre-Defined Frailty Measurement Criteria   Frailty Mortality\                                                   *Model used*   *I* ^2^                               AMSTAR\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     Duration                                                                                                                HR/RRs (95% CI)                                                                                                           Quality Rating
  ---------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------- --------------------------------- ----------------------------- ---------------------------------------------------------------------------------------- ------------------------ ------------ ----------------------------------------------------------------------------------------------------------- ---------------------------- ------------------------ ---------------------- ------------------------------------------ -------------------------------------------------------------------- -------------- ------------------------------------- ----------------
  Anand et al. \[[@B33-geriatrics-05-00017]\]          Medline, Embase and Cinahl                                                                                                         1 January 2000 to 1 June 2015     7                             TAVI patients                                                                            Mean age: 81--86 y       48--66%      Switzerland, Canada, Germany, Netherlands, Italy, USA                                                       \>30 days                    3159 (23.2%)             Frailty                Any                                        1.63 (1.34--1.97) ^a^                                                RE             66.0%                                 Moderate

  Huang et al. \[[@B34-geriatrics-05-00017]\]          PubMed, Embase and Cochrane library                                                                                                Inception to January 2018         10                            TAVR patients                                                                            NR                       NR           USA, Poland, Germany, Spain, Japan, Switzerland                                                             \>6 months                   2992 (32.5%)             Frailty                Any                                        2.81 (1.90--4.15) ^b^                                                RE             84.0%                                 Moderate

  Ida et al. \[[@B35-geriatrics-05-00017]\]            Medline, Cochrane central and [Clinicaltrials.gov](Clinicaltrials.gov)                                                             Inception to 1 December 2018      4 (Frail vs. non-frail)\      Patients with diabetes                                                                   Mean age: 56--76 y       46--67%      Italy, USA, Spain, Taiwan                                                                                   3--12 y                      563,761\                 Frailty, Pre-frailty   Any                                        Frailty: 1.35 (1.05--1.74) ^a^\                                      RE             92.0% (Frailty)\                      Moderate
                                                                                                                                                                                                                            2 (pre-frail vs. non-frail)                                                                                                                                                                                                                                                                           (NR)                                                                                       Pre-frailty: 1.09 (1.01--1.17) ^a^                                                  89.0% (Pre-frailty)                   

  Kojima et al. \[[@B36-geriatrics-05-00017]\]         Embase, Scopus, Medline, Cinahl PsycINFO and Google scholar                                                                        Inception to March 2018           3                             Community-dwelling middle-aged and older adults                                          Mean age: ≥59.9 y        0--53.4%     UK, Mexico, Italy, Belgium, Denmark, France, Greece, Italy, Netherlands, Spain, Sweden, Switzerland         2.4--4.3 y                   9273 (NR)                Frailty, Pre-frailty   FRAIL scale                                Frailty: 3.53 (1.66--7.49) ^a\*\*^\                                  RE             79.0% (Frailty)\                      Moderate
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             Pre-frailty: 1.75 (1.14--2.70) ^a^                                                  64.0% (Pre-frailty)                   

  Man et al. \[[@B37-geriatrics-05-00017]\]            PubMed and Embase                                                                                                                  Inception to October 1 2018       5 (Frailty)\                  Patients with ACS                                                                        ≥65 y                    32.8--48.9   Canada, Spain, France, Sweden                                                                               ≥12 months                   1270 (38.4%)             Frailty, Pre-frailty   Any                                        Frailty: 2.44 (1.92--3.12) ^a^\                                      FE             0.0% (Frailty),\                      Critically low
                                                                                                                                                                                                                            3 (Pre-frailty)                                                                                                                                                                                                                                                                                                                                                                                  Pre-frailty:1.65 (1.01--2.69) ^a^                                                   0.0% (pre-frailty)                    

  Muscedere et al. \[[@B38-geriatrics-05-00017]\]      Cochrane central, Medline, Embase, PubMed, Cinahl and [Clinicaltrials.gov](Clinicaltrials.gov)                                     Inception to April 2017           6                             Patients admitted to the ICU                                                             Mean age: 57.1--84.0 y   NR           USA, Canada, Turkey, France                                                                                 \>6 months                   2484 (42.8%)             Frailty                Any                                        1.53 (1.40--1.68) ^b^                                                RE             0.0%                                  Moderate

  Panayi et al. \[[@B39-geriatrics-05-00017]\]         PubMed and Cochrane central                                                                                                        Inception to 1 January 2018       11                            Surgical patients (All surgeries)                                                        NR                       NR           USA, Canada                                                                                                 NR                           523,598 (70.7%)          Frailty                Modified frailty index (mFI)               4.19 (2.96--5.12) ^b^                                                RE             91.0%                                 Moderate

  Salazar et al. \[[@B40-geriatrics-05-00017]\]        Medline, Embase, Scopus, Cochrane Database of Systematic Reviews, Cochrane Central, and [Clinicaltrials.gov](Clinicaltrials.gov)   Inception to\                     3                             Patients with multiple myeloma                                                           Median age: 58--74       NR           Italy, Czech Republic, Netherlands, China, Germany                                                          13--28 months                1622 (NR)                Frailty                Any                                        2.17 (1.00--2.34) ^a^                                                RE             33.7%                                 Critically low
                                                                                                                                                                                          August 2018                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  

  Sandini et al. \[[@B41-geriatrics-05-00017]\]        Medline, Embase, PubMed, Cochrane and Scopus libraries                                                                             1990 to January 2017              8                             Elective major abdominal surgery patients                                                NR                       NR           USA, Korea, Norway, Netherlands                                                                             Up to 1 y                    16,825 (NR)              Frailty                Any                                        2.71 (1.63--4.49) ^a^                                                RE             88.3%                                 Moderate

  Shu-Fang et al. \[[@B42-geriatrics-05-00017]\]       Medline and CINAHL databases and the Cochrane Library                                                                              January 2001 to July 2014         11                            Community-dwelling older adults                                                          ≥65 y                    NR           France, Spain, USA, Israel, Finland                                                                         1.5--10 y                    35538 (NR)               Frailty, Pre-frailty   Fried (CHS) criteria                       Frailty:2.00 (1.73--2.32) ^a^\                                       RE             61.7% (Frailty)\                      Moderate
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             Pre-frailty: 1.34 (1.26--1.41) ^a^                                                  0.0% (Pre-frailty)                    

  Thongprayoon et al. \[[@B43-geriatrics-05-00017]\]   Medline, Embase, the Cochrane Central Register of Controlled Trials, and the Cochrane Database of Systematic Reviews               Inception to November 2016        8                             TAVR patients                                                                            NR                       NR           USA, Germany, France                                                                                        NR                           10,498 (NR)              Frailty                Any                                        2.01 (1.44--2.80) ^b^                                                RE             58.0%                                 Moderate

  Tse et al. \[[@B44-geriatrics-05-00017]\]            PubMed and EMBASE                                                                                                                  Inception to July 23 2017         8                             Patients who have undergone PCI                                                          Mean age 69 y            32           Spain, Indonesia, UK, Japan, USA                                                                            Mean 2.5 y                   2332 (NR)                Frailty                Any                                        2.97 (1.56--5.66) ^a^                                                RE             79.0%                                 Low

  Tse et al. \[[@B45-geriatrics-05-00017]\]            PubMed and Embase                                                                                                                  Inception to September 11, 2017   7                             Advanced Heart Failure Patients Undergoing Left Ventricular Assist Device Implantation   Mean age 48--69 y        20.8                                                                                                                     Mean 13 months               2942 (13.5%)             Frailty                Any                                        1.44 (1.15--1.80) ^a^                                                FE             0.0%                                  Moderate

  Vermeiren et al. \[[@B46-geriatrics-05-00017]\]      PubMed, Web of Knowledge and PsycINFO                                                                                              Inception to January 2016         17                            Community-dwelling older adults                                                          ≥65 y                    NR           USA, France, Spain, Cuba, Dominican Republic, Venezuela, Mexico, Peru, India, China, Italy, Finland         10--120 months               150,763 (NR)             Frailty                Any                                        1.83 (1.68--1.98) ^a/b^                                              n.s            98.0%                                 Low

  Wang et al. \[[@B47-geriatrics-05-00017]\]           Medline, Embase, Cochrane, Scopus                                                                                                  Inception to September 2017       9                             Patients who have undergone major vascular surgery                                       Mean age ≥59.1 y         NR           Canada, USA, Japan                                                                                          1--8.4 y                     1957 (35.5%)             Frailty                Any                                        2.22 (1.81--2.73) ^a^                                                RE             0.0%                                  Moderate

  Wang et al. \[[@B48-geriatrics-05-00017]\]           PubMed, Embase, Cochrane, Web of science                                                                                           Inception to November 8 2017      6                             Patients with heart failure                                                              Mean age: 82.6 y         17.6         USA, Italy, Spain                                                                                           \>30 days                    1747 (53.0%)             Frailty                Any                                        1.70 (1.41--2.04) ^a^                                                FE             0.0%                                  Low

  Yang et al. \[[@B49-geriatrics-05-00017]\]           Medline, Embase, Cochrane Central                                                                                                  January 1966 to March 2018        8                             Patients with chronic heart failure                                                      Mean age: 73.4 y         40.1         USA, Italy, Australia, Spain                                                                                NR                           2645 (50.7%)             Frailty                Any                                        1.54 (1.34--1.75) ^a^                                                RE             0.0%                                  Moderate

  Zhang et al. \[[@B50-geriatrics-05-00017]\]          Medline, Embase, Cochrane Central                                                                                                  Inception to October 2018         14                            Nursing home residents                                                                   Mean age:84.9            72.1         France, Spain, Canada, Belgium, USA, Japan, Poland, China, Australia                                        0.5--9 y                     9076 (53.9%)             Frailty                Any                                        1.88 (1.57--2.25) ^a^                                                RE             47.8%                                 Moderate

  Zhang et al. \[[@B51-geriatrics-05-00017]\]          Medline, Embase, Cochrane Central                                                                                                  Inception to October 2018         3                             Heart failure patients                                                                   NR                       NR           USA, Spain                                                                                                  NR                           NR                       Frailty                Any                                        Pre-frailty: 1.51 (0.99--2.31) ^a^                                   RE             0.0%                                  Critically low

  Zhang et al. \[[@B52-geriatrics-05-00017]\]          PubMed and Embase                                                                                                                  Inception to December 3 2017      20                            Patients with heart failure                                                              Mean age: 79.9 y         11.1--60.9   USA, Spain, Italy, Australia, Canada, UK, Hong Kong                                                         0.5--12 y                    17201 (9.2--76%)         Frailty                Any                                        1.59 (1.39--1.82) ^a^\                                               RE             55.0%                                 Low

  Dou et al. \[[@B53-geriatrics-05-00017]\]            PubMed and Embase                                                                                                                  Inception to July 1 2018          7                             Patients with ACS                                                                        ≥65 y                    NR           Spain, France, Sweden, Canada, Japan, South Africa, Scandinavia, India, East Asia, Australia, New Zealand   In hospital to 56.4 months   6658 (12.3%)             Frailty                Any                                        Frailty: 2.65 (1.81--3.89) ^a^\                                      RE             60.2% (Frailty)\                      Low
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             Pre-frailty: 1.41 (1.19--1.66) ^a^                                                  0.0% (Pre-frailty)                    

  Zhang et al. \[[@B54-geriatrics-05-00017]\]          PubMed, Web of Science, Embase and Cochrane Central databases                                                                      Inception to June 2019            11                            Patients with CKD or end-stage renal disease                                             Mean age: \>45.0 y                    USA, South Korea, India                                                                                     1--17 y                      127037 (7.9--82.0%)      Frailty                Fried (CHS)                                1.95 (1.50--2.53) ^a^                                                RE             82.0%                                 Low

  Houghton et al. \[[@B55-geriatrics-05-00017]\]       Cinahl, PsycInfo, and Scopus                                                                                                       inception to September, 2018      9                             Vascular surgery patients                                                                NR                                    USA, Japan, UK                                                                                              NR                           2904                     Frailty                Any                                        1.85 (1.31--2.62) ^a^                                                RE             74.0%                                 Low

  Cunha et al.\                                        PubMed, Embase, Web of Science, Lilacs, Cinahl, PsycInfo and Google Scholar                                                        Inception to March 2019           4 (Frailty); 3\               Hospitalized patients                                                                    NR                                    NR                                                                                                          7--12 months                 2119 (86.6%)             Frailty, Pre-frailty   Any                                        Frailty: 7.95 (4.88--12.96)^a^, Pre-frailty: 3.65 (1.41--9.43) ^a^   RE             0.0% (Frailty), 28.0% (pre-frailty)   Moderate
  \[[@B56-geriatrics-05-00017]\]                                                                                                                                                                                            (Pre-frailty)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              

  Zhang et al. \[[@B57-geriatrics-05-00017]\]          Medline, Embase, and Cochrane Central                                                                                              Inception to December 2018                                      Patients with ACS                                                                        NR                                    NR                                                                                                          15--60 Months                4665 (12.8%)             Frailty                Any                                        1.66 (1.35--2.05) ^a^                                                FE             11.0%                                 Low
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

a = hazard ratio, b = risk ratio, HF = heart failure, ACS = acute coronary syndrome, CI = confidence interval, CKD = chronic kidney disease, FE = fixed effect model, ICU = intensive care unit; n.s. = not stated, RE = random effect model, TAVI = transcatheter aortic valve implantation patients; TAVR = transcatheter aortic valve replacement, LVAD = left ventricular assist device implantation;\*\* in this study the reference group was only robust people.

[^1]: These authors contributed equally to this work.
